卡维地洛治疗轻中度稳定性慢性心力衰竭耐受性和安全性研究

目的：评估卡维地洛治疗轻中度稳定性慢性心力衰竭的I临床耐受性和安全性。方法：482例符合轻中度慢性心衰标准的患者在常规治疗后，病情基本稳定的基础上加用卡维地洛。卡维地洛从小剂量3．125mg每日两次开始，每两周递增一次，直至靶剂量25mg每天2次或最大耐受剂量。治疗前后分别对心功能(NYHA)分级、心衰评分、血压、心率等体征及实验室(血常规，肝肾功能及心电图等)检查进行检测，评判疗效、耐受性及安全性。结果：用卡维地洛治疗后心功能明显改善，心衰评分下降，提示生活质量改善，同时不良反应少，安全性好。60％的患者可以达到推荐靶剂量。结论：卡维地洛治疗轻中度慢性稳定性心衰耐受性和安全性良好。

Tolerance and safety study of Carvedilol (ilatrend)treatment in 482 patients with mild and moderate stable chronic heart failure

Objective To evaluate tolerance and safety of carvedilol in patients with mild and moderate chronic stable heart failure. Methods Carvedilol was added on basic therapy in 482 patients from low dosage (3.125 mg bid), and up-titrated in an interval of two weeks till target dosage of 25 mg bid or maximal tolerance dosage. Before and after treatment with carvedilol,NYHA class, left ventricular dysfunction questionnaire(LVD-36),signs including blood pressure and heart rate,laboratory test(blood routine, liver, renal function and EKG) were performed. Results After treatment with carvedilol, NYHA class was improved significantly, LVD questionnaire showed quality of life improved significantly. Adverse events were seldom observed. 60% patients can tolerate targeted dosage. Conclusion Carvedilol is effective and safe in CHF patients with favorable tolerance.